Estimation of treatment effects in early-phase randomized clinical trials involving external control data
- 12 October 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 34 (5) , 680-699
Abstract
There are good reasons to perform a randomized controlled trial (RCT) even in early phases of clinical development. However, the low sample sizes in those settings lead to high variability of the treatment effect estimate. The variability could be reduced by adding external control data if available. For the common setting of suitable subject-level control group data only available from one external (clinical trial or real-world) data source, we evaluate different analysis options for estimating the treatment effect via hazard ratios. The impact of the external control data is usually guided by the level of similarity with the current RCT data. Such level of similarity can be determined via outcome and/or baseline covariate data comparisons. We provide an overview over existing methods, propose a novel option for a combined assessment of outcome and baseline data, and compare a selected set of approaches in a simulation study under varying assumptions regarding observable and unobservable confounder distributions using a time-to-event model. Our various simulation scenarios also reflect the differences between external clinical trial and real-world data. Data combinations via simple outcome-based borrowing or simple propensity score weighting with baseline covariate data are not recommended. Analysis options which conflate outcome and baseline covariate data perform best in our simulation study.Keywords
Funding Information
- No funding
This publication has 29 references indexed in Scilit:
- Do single‐arm trials have a role in drug development plans incorporating randomised trials?Pharmaceutical Statistics, 2015
- Does Cox analysis of a randomized survival study yield a causal treatment effect?Lifetime Data Analysis, 2015
- Robust meta‐analytic‐predictive priors in clinical trials with historical control informationBiometrics, 2014
- Use of historical control data for assessing treatment effects in clinical trialsPharmaceutical Statistics, 2013
- A tool for assessing the feasibility of comparative effectiveness researchComparative Effectiveness Research, 2013
- Randomized Phase II Trials: Inevitable or Inadvisable?Journal of Clinical Oncology, 2010
- Matching Methods for Causal Inference: A Review and a Look ForwardStatistical Science, 2010
- Summarizing historical information on controls in clinical trialsClinical Trials, 2010
- The estimation of average hazard ratios by weighted Cox regressionStatistics in Medicine, 2009
- The relationship between the power prior and hierarchical modelsBayesian Analysis, 2006